NBY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NovaBay Pharmaceuticals Inc (NBY) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows weak financial performance, no significant trading trends, and lacks positive catalysts. Additionally, technical indicators suggest a bearish trend, and there are no strong proprietary trading signals to support a buy decision.
The stock is currently in a bearish trend. The MACD histogram is negative (-0.297) and contracting, RSI is at 16.811 indicating oversold conditions, and moving averages are converging. Key support and resistance levels suggest significant downside risk with S1 at 0.641 and S2 at 0.275, while the pre-market price is 0.589.
NULL identified. No recent news or significant trading trends from hedge funds, insiders, or Congress.
Weak financial performance in Q3 2025, with net income dropping 41.68% YoY and EPS down 88.54% YoY. No significant trading trends or positive sentiment from options data.
In Q3 2025, revenue remained flat YoY at $521,000. Net income dropped significantly by 41.68% YoY to -$1,293,000, and EPS fell 88.54% YoY to -0.22. Gross margin remained stagnant at 8.06%.
No analyst rating or price target data available for evaluation.
